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Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in 
clinical practice, affecting approximately 0.% of the population.1 The prevalence of 
AF is strongly age-dependent, affecting approximately 1% of persons aged 65 years 
and 5% of individuals older than 65 years.2 AF is also associated with an increase in 
the relative risk of mortality ranging from 1.3 to 2.34, independent of other risk factors 
as well as an increasing morbidity and adversely affects quality of life.3-5 Unfortunately, 
current rhythm control strategies are far from ideal. Data from five comparative stud-
ies of a primary rate control vs. rhythm control strategy for patients with a history of 
AF failed to show a significant superiority of rhythm control.6-10 In fact, these studies 
merely emphasized the limited efficacy and high side-effect profile of the currently 
available anti-arrhythmic drugs.11
I N f L A m m A t I O N  A N D  A t r I A L  f I b r I L L A t I O N
There is now an increasing body of evidence linking inflammation to a broad 
spectrum of cardiovascular conditions, such as coronary artery disease (CAD), insulin 
resistance and diabetes mellitus, and hypertension.12-16 In addition, there is emerging 
data to support the association between inflammation and AF.17-18
The pathophysiology of AF is highly complex. It is now recognized that the develop-
ment of AF leads to functional changes within the atria that perpetuate the arrhythmia 
(‘AF begets AF’), by a process known as electrical remodeling.1 Structural remodeling 
of the atria occurs in parallel with the changes of electrical remodeling. The struc-
tural changes that define this structural remodeling include left atrial dilatation and 
increasing atrial fibrosis.20 Key to this fibrotic process is the deposition of increased 
amounts of connective tissue between individual cells and with the deposition of 
large amounts of collagen and fibronectin.21 Bruins et al. were the first to propose the 
inflammation-AF hypothesis, following their observations of an increased frequency 
of AF after coronary artery bypass surgery. They noted that the peak incidence of 
AF occurred on the second and third post-operative days, which coincided with the 
peak elevation of CRP levels.22
Histological evidence to support the association between inflammation and AF has 
been derived from several sources.23-27 Results of atrial biopsies taken from patients in 
AF compared with controls have demonstrated evidence of inflammatory infiltrates 
and oxidative damage within the atrial tissue. The inflammatory markers that have 
been most frequently studied are high-sensitivity C reactive protein (hs-CRP) and 
interleukin (IL)-6. Levels of hs-CRP have been noted to be higher among patients with 
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AF compared with controls in sinus rhythm. Also, persistent 
AF patients have higher hs-CRP levels than paroxysmal AF 
patients, and both have higher levels than controls.28-35 Fur-
thermore, a longer duration of AF is associated with higher 
hs-CRP levels and larger left atrial dimensions, supporting a 
link between the burden of AF, inflammation, and structural 
remodelling. In both crosssectional and longitudinal studies, 
hs-CRP has remained a consistent and significant predictor 
of early AF relapse after successful cardioversion, even after 
adjustment for risk factors for AF, such as hypertension and 
CAD. hs-CRP has also been shown to be predictive of subse-
quent future development of new cases of AF among a large 
cohort of patients in sinus rhythm.30-32,34 IL-6 levels would be 
raised in patients with AF compared with healthy controls. 
There have been five studies which have investigated the 
relationship between IL-6 and AF. Four of these studies found 
increased levels of IL-6 in patients with AF compared with 
healthy controls, with one failing to find any association.28-
30,35,36 So far, there has been only one study that has looked 
into the possible association between TNF-a and AF. This 
was a very small study and did not adjust for confounding 
factors; however, it did demonstrate increased levels of TNF-a 
in patients with AF compared with healthy controls in sinus 
rhythm.28 Finally, there appears to be a relationship between 
elevated white blood cell count as a marker of inflammation 
and the development of AF after cardiac surgery in 181 con-
secutive patients undergoing coronary bypass or cardiac valve 
surgery, even after multivariate analyses.37 
There is histological evidence to confirm that AF (both 
persistent and paroxysmal) leads to altered angiotensin II re-
ceptor expression. In a key paper, Cardin et al. were able to link 
increased atrial expression of angiotensin II receptors with in-
creased atrial cell death and leukocyte infiltration supporting 
a potential link between the RAAS, inflammation, and AF. 
Furthermore, there is now evidence linking polymorphisms 
in the renin–angiotensin system (RAS) gene with an increase 
risk of subsequent AF development, further supporting the 
role of the RAAS in the development of AF.38-43
Although there appears to be a link between inflamma-
tion and AF, one of the key questions is whether the observed 
inflammation in AF increases the risk of thromboembolism as 
has been demonstrated for atherosclerotic models. Conway et 
al. were the first to confirm this putative link between inflam-
mation and complications of AF. In a small pilot study, they 
showed that elevated IL-6 levels were an independent predic-
tor of the composite of stroke or death among a cohort of 77 
high-risk AF patients.44 This observation was complemented 
by data from Thambidorai et al. which showed that trans-es-
ophageal risk factors for stroke were greater for patients with 
elevated hs-CRP compared those with normal levels among 
104 patients with AF.45 Hence, there appears to be an estab-
lished link between inflammation, AF, and thrombosis. 
P r E v E N t I N G  A f  b Y  m O D U L A t I N G  t H E 
I N f L A m m A t O r Y  s t A t E
There have been a large number of studies that have ana-
lyzed the relationship between rAAs inhibition and Af. In 
a recent large meta-analysis (56308 patients) incorporating 
11 of the 12 randomized trials using either ACE-inhibitors or 
ARBs for the prevention of AF, Healey et al. demonstrated 
a favourable effect of RAAS inhibition in the primary and 
secondary prevention of AF. They concluded that ACE-in-
hibitors/ARBs reduced the overall risk of AF by 28% [5% 
confidence interval (CI) 15–40%, P:0.0002] across a broad 
spectrum of patient subgroups (including patients with hy-
pertension, heart failure, post-myocardial infarction, and 
postcardioversion). Furthermore, the reduction in AF was 
similar independent of whether an ACE-inhibitor or an ARB 
was the main drug group used (ACE-inhibitors: 28%, P:0.01; 
ARBs: 2%, P:0.00002).46 
There have been several putative mechanisms to explain 
the favourable actions of ACE-inhibitors and ARBs in the 
prevention of AF: decreased atrial stretch; lowered end-
diastolic left ventricular pressure and subsequent left atrial 
pressure; the prevention of atrial fibrosis; the modification 
of sympathetic tone, alteration in ion currents and atrial 
refractoriness, and direct anti-arrhythmic effects.47 However, 
given the demonstrated important role of the RAAS in in-
flammation and AF, it could be postulated that interruption 
of the RAAS may exact positive effects upon the left atrium 
by reducing atrial inflammation, oxidative stress, and reduce 
atrial remodelling. 
statins, 3-hydroxy-3-methylglutaryl coenzyme A reduct-
ase inhibitors, remain the most powerful and effective lipid-
lowering drugs. A series of landmark clinical trials have estab-
lished statins as effective agents in the primary and secondary 
prevention of coronary disease. It has become increasingly 
apparent that the benefits of statins extend to mechanisms 
beyond their cholesterol-reducing effects. These ‘pleiotropic’ 
(multiple) effects include improved endothelial function with 
increased nitric oxide bioavailability, anti-thrombotic effects, 
enhanced stability of the atherosclerotic plaque, and decreased 
oxidative stress and vascular inflammation. If AF is indeed 
linked to inflammation then statins would offer a potentially 
preventative role in AF. There have been five studies so far 
that have analyzed the efficacy of statins in the prevention 
of AF.48-52 Four of these studies showed favourable effects 
of statins to reduce the incidence of AF, with only one study 
reporting negative results. Siu et al were the first to study the 
prevention of AF with statins. They retrospectively studied 
62 patients with lone persistent AF lasting 3 months who 
underwent direct current cardioversion, and observed that 
statin- treated patients (n = 10) had less recurrent AF than the 
control group of 52 patients (40 vs. 84%, P : 0.0007); however, 
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this was a very small and underpowered observational study.53 
In a much larger observational study, Young- Xu et al.studied 
a cohort of 44 patients with CAD at high risk of AF. They 
observed a significantly lower rate of new AF development 
among statin users (%) compared with non-users (15%). Of 
note, the potential impact of statins on AF development was 
independent of its cholesterol-lowering ability. Also, the ef-
ficacy of statins in preventing AF appeared to correlate with 
the length of statin use, with longer statin use being associated 
with greater protection against the subsequent development 
of AF.54 In the largest study so far, Hanna et al. performed 
a cross-sectional analysis of 25 000 patients enrolled in the 
multicenter Guidant-sponsored Advancement Heart Failure 
Registry; of these patients, 7027 patients (27%) developed AF, 
and statin therapy led to a 23% reduction in AF, when com-
pared with those not treated, even after multivariate analysis 
(odds ratio for AF 0.685; P , 0.001).55
s t E r O I D s 
In a double-blind study, Dernelis and Panaretou rand-
omized 104 patients with first presentation persistent AF to 
low-dose glucocorticoid therapy (16 mg methyl prednisolone 
for 4 weeks tapered to 4 mg for 3 months) or placebo.56 A 
primary rhythm control strategy involving amiodarone & 
cardioversion was adopted in all of the patients as part of the 
trial protocol. All patients were successfully cardioverted and 
were commenced on oral propafenone post-cardioversion. 
The authors found that methyl prednisolone significantly 
reduced the primary endpoint of AF recurrence (50% in the 
placebo group vs. .6% in the glucocorticoid group) as well as 
the extended endpoint of permanent AF (2% in the placebo 
group vs. 2% in the glucocorticoid group). In addition, hs-CRP 
concentrations were a significant predictor of the primary 
end-point, with higher hs-CRP levels being predictive of AF 
recurrence, and vice versa. In addition, methyl prednisolone 
significantly lowered hs-CRP by an average of 80% within 
the first month, and this reduction was maintained for the 
duration of the 30-month study (P:0.001). The authors also 
demonstrated that the risk of AF recurrence was increased 
by approximately seven times for each 1 mg/dL increase in 
plasma levels of hs-CRP, providing a strong link between the 
degree of inflammation and the burden of AF. 
f I s H  O I L s 
Dietary intake of polyunsaturated fatty acids (PUFAs), 
notably omega (n)-3 fatty acids, have been to shown to have 
favourable effects on cardiovascular outcomes. Their efficacy 
can only be partly explained by improvement in lipid profile 
and there is mounting evidence to support potential anti-in-
flammatory and antioxidant properties of oily fish. Indeed, 
n-3 fatty acids have anti-inflammatory properties and are 
frequently used clinically to treat symptoms of inflammatory 
diseases, such as rheumatoid arthritis or Crohn’s disease.57,58 
In a prospective, population-based cohort of 4815 older (>65 
years) Mozaffarian et al. demonstrated that consumption of 
high levels of fish containing n-3 fatty acids was associated with 
a lower incidence of subsequent AF development.5 However, 
these results are challenged by an even larger prospective study 
of 47 4 participants (mean age: 56 years) which investigated 
the relation between the consumption of n-3 fatty acids from 
fish, by use of a detailed semi-quantitative food questionnaire, 
and risk of AF or flutter, but found that consumption of n-3 
fatty acids from fish was not associated with a reduction in risk 
of AF or atrial flutter.60 Finally, in a recently published study 
of 160 patients pre-treatment with omega-3 fatty acids reduced 
the incidence of AF post-coronary artery bypass surgery by 
58% compared with patients treated with usual care only.61 In 
this study, 2 g/day of PUFAs was administered at least 7 days 
before surgery and continued until discharge. In addition, 
treatment with fish oils reduced the length of hospitalization 
from 8.2 to 7.3 days (P :0.017).
v I t A m I N  c 
Ascorbic acid (vitamin C) is potent oxygen scavenger, 
which may potentially modulate the inflammatory and oxi-
dative abnormalities associated with AF.62 In a novel study, 
Carnes et al. gave supplemental ascorbate to 43 patients 
before, and for 5 days following, cardiac bypass graft surgery, 
and found that ascorbate significantly reduced the incidence 
of post-operative AF (16.3% in ascorbate treated vs. 34.% in 
control subjects).63 They also showed that atrial peroxynitrate 
(a known ROS) formation was increased during rapid atrial 
pacing and that atrial ascorbate levels were reduced follow-
ing atrial pacing. The current evidence would thus support 
the hypothesis that vitamin C attenuates atrial electrophysi-
ological remodelling and reduces AF burden, possibly via the 
scavenging peroxynitrite and other reactive oxygen species, 
and reducing the inflammatory substrate.
A t r I A L  f I b r I L L A t I O N  A N D  A t r I A L 
f I b r O s I s
Which mechanism of AF is characteristic in a setting of 
atrial fibrosis is unknown, as evidence exists for both reentry 
and discrete, stable foci as an AF mechanism in dogs with 
pacing-induced CHF. Li et al showed a mechanism of mac-
roreentry with conduction abnormalities providing the milieu 
for AF propagation before termination with dofetilide, an IKr 
channel blocker. In contrast, this study also showed in a model 
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of rapid atrial pacing that multiple wavelets were the likely 
mechanism, and dofetilide was ineffective in terminating AF. 
The rapid atrial pacing model has atrial electrical remodeling 
and little in the way of structural remodeling. The CHF model 
does not have any significant atrial electrical remodeling (at 
least none that contributes substantially to the AF substrate) 
but has substantial atrial structural remodeling.64,65 Stambler 
et al suggested that AF in the setting of CHF in dogs was focal 
in origin caused by triggered activity. This triggered activity 
was shown to be produced by delayed afterdepolarizations 
initiated by intracellular Ca+2􏰂 overload. Drugs that reduced
intracellular Ca2􏰂 levels (verapamil, flunarizine, ryanodine)
all terminated AF.66 Okuyama et al performed high-density 
mapping of the pulmonary veins during AF in dogs with CHF. 
In half of the AF episodes recorded in the CHF model, focal 
activation was seen from within the vein independent of the 
LA. This type of activation was not seen in any of the AF 
occurring in controls, as the pulmonary veins were activated 
passively from wavefronts originating from the LA.67
The precise mechanisms and signaling pathways involved 
in the development of atrial fibrosis are unknown. It appears, 
however, that the atrium is more susceptible to atrial fibrosis 
than is the ventricle, and currently three interrelated pathways 
appear to be involved the renin–angiotensin system, TGF-1, 
and the oxidative stress pathways.
Transgenic mouse models of angiotensin- converting en-
zyme (ACE) overexpression have been shown to result in atrial 
fibrosis.68 Several clinical and animal studies have shown that 
use of ACE inhibitors with CHF reduces the occurrence of AF 
and AF vulnerability.6 Use of ACE inhibitors has also been 
shown to prevent the progression of paroxysmal AF to chronic 
AF and to increase the efficacy of electrical cardioversion of 
AF.70,71 These clinical data suggest that ACE inhibitors may be 
useful in delaying progression of atrial fibrosis and AF. 
In a transgenic mouse model that overexpresses a consti-
tutively active transforming growth factor TGF-β1, selective 
atrial interstitial fibrosis was observed, but ventricular histol-
ogy was normal. This occurred despite equal overexpression of 
TGF-1 in the atrium and the ventricles. The increase in atrial 
fibrosis was shown to correspond to an increase in conduction 
heterogeneity and AF vulnerability.72 Cellular electrophysiol-
ogy was not affected by the TGF-β1. This study demonstrated 
that atrial fibrosis alone is a sufficient substrate for AF, and 
that TGF-β1 may play an important role in the genesis of 
atrial fibrosis. In another study by the same group, the drug 
pirfenidone was used to target the expression of TGF-β1. 
Pirfenidone has been shown to significantly reduce expression 
of TGF- β1, with a concomitant reduction in tissue fibrosis in 
multiple experimental animal models.65 Increases in AngII 
and activated TGF-β1 concentrations reciprocally enhance 
each other’s production73 and induce expression of additional 
profibrotic molecules in fibroblasts74 creating positive feedback 
cycles for fibrosis. Mechanical stretch induces collagen syn-
thesis75 along with increased AngII and TGF-β1 expression 
in cardiac fibroblasts76, and thus chronic atrial dilation may 
contribute to structural remodeling and the domestication of 
AF.77 Fibroblast stretch- sensing mechanisms show exquisite 
sensitivity, with different types of deformation causing dif-
ferential ECM expression profiles. In addition to profibrotic 
actions, mechanical stretch of fibroblasts can directly modu-
late myocyte electrical activity, a potentially proarrhythmic 
mechanism called mechanoelectric feedback.78
c O N c L U s I O N
Inflammation and fibrosis play an important role in the 
development of AF. Therefore inflammation and fibrosis may 
constitute new therapeutic targets in the management of AF. 
More studies are needed to clarify these important issues.
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